Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,091,042
  • Shares Outstanding, K 61,982
  • Annual Sales, $ 434,430 K
  • Annual Income, $ 275,190 K
  • EBIT $ 27 M
  • EBITDA $ 21 M
  • 60-Month Beta 2.26
  • Price/Sales 7.28
  • Price/Cash Flow 11.30
  • Price/Book 4.59

Options Overview Details

View History
  • Implied Volatility 47.84% ( -5.42%)
  • Historical Volatility 41.83%
  • IV Percentile 6%
  • IV Rank 8.01%
  • IV High 138.06% on 02/21/25
  • IV Low 39.99% on 08/21/24
  • Put/Call Vol Ratio 0.37
  • Today's Volume 123
  • Volume Avg (30-Day) 220
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 8,512
  • Open Int (30-Day) 8,374

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.53
  • Number of Estimates 6
  • High Estimate -0.24
  • Low Estimate -0.76
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -6.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.38 +0.65%
on 07/08/25
57.70 -13.86%
on 06/10/25
-4.68 (-8.61%)
since 06/06/25
3-Month
39.60 +25.51%
on 04/09/25
57.70 -13.86%
on 06/10/25
+8.03 (+19.27%)
since 04/08/25
52-Week
32.50 +52.92%
on 08/05/24
60.60 -17.99%
on 03/12/25
+15.01 (+43.27%)
since 07/08/24

Most Recent Stories

More News
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors

PTGX : 49.70 (-0.34%)
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below

PTGX : 49.70 (-0.34%)
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present...

PTGX : 49.70 (-0.34%)
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16

PTGX : 49.70 (-0.34%)
Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics: Q1 Earnings Snapshot

PTGX : 49.70 (-0.34%)
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st

PTGX : 49.70 (-0.34%)
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American...

PTGX : 49.70 (-0.34%)
Protagonist Therapeutics Reports Granting of Inducement Award

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based...

PTGX : 49.70 (-0.34%)
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16

PTGX : 49.70 (-0.34%)
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others

PTGX : 49.70 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 51.33
2nd Resistance Point 50.87
1st Resistance Point 50.29
Last Price 49.70
1st Support Level 49.25
2nd Support Level 48.79
3rd Support Level 48.21

See More

52-Week High 60.60
Fibonacci 61.8% 49.87
Last Price 49.70
Fibonacci 50% 46.55
Fibonacci 38.2% 43.23
52-Week Low 32.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar